Pacific Biosciences of California (PACB) to Release Quarterly Earnings on Thursday

Pacific Biosciences of California (NASDAQ:PACB) will likely be issuing its quarterly earnings data after the market closes on Thursday, February 13th. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $40.68 million for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Pacific Biosciences of California Price Performance

PACB opened at $1.33 on Wednesday. Pacific Biosciences of California has a fifty-two week low of $1.16 and a fifty-two week high of $6.83. The firm has a market capitalization of $364.23 million, a P/E ratio of -0.91 and a beta of 1.92. The company’s 50-day moving average is $1.83 and its 200 day moving average is $1.80. The company has a debt-to-equity ratio of 1.97, a current ratio of 9.74 and a quick ratio of 8.64.

Insider Activity

In related news, insider Oene Mark Van sold 34,405 shares of the stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $2.03, for a total transaction of $69,842.15. Following the sale, the insider now owns 1,597,454 shares of the company’s stock, valued at approximately $3,242,831.62. This represents a 2.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 2.40% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. StockNews.com upgraded Pacific Biosciences of California to a “sell” rating in a research note on Thursday, January 9th. Scotiabank cut their price objective on Pacific Biosciences of California from $7.00 to $6.00 and set a “sector outperform” rating on the stock in a research report on Monday, November 11th. UBS Group lowered Pacific Biosciences of California from a “buy” rating to a “neutral” rating and set a $2.00 target price for the company. in a research report on Monday, November 11th. The Goldman Sachs Group cut their price target on shares of Pacific Biosciences of California from $2.25 to $1.75 and set a “neutral” rating on the stock in a report on Thursday, January 23rd. Finally, Piper Sandler raised their price objective on shares of Pacific Biosciences of California from $2.00 to $2.50 and gave the stock a “neutral” rating in a report on Monday, November 11th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $2.89.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.